Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic
  • Search Hotels in Burlingame

  • ROOMS:

CD Formulation Launches API Chemical Modification Services to Address Drug Solubility, Bioavailability, and Dissolution Rate Issues

By: Get News

New York, USA – May 26, 2022 – Having abundant expertise in drug formulation and pharmaceutical preparation, the New York-based CRO company CD Formulation recently announces that it is now capable of conducting a wide range of API chemical modification services, including pH modification drug molecular service, drug salt formation service, drug pegylation service, and different groups of precursor drug design service, to help researchers address some of the long-standing issues in drug development like drug solubility, bioavailability, and dissolution rate.

Solubility, bioavailability, and dissolution rate are among the most important parameters to measure the likelihood of achieving desired concentration of drug in systemic circulation to obtain the anticipated pharmacological response ultimately.

“Truly knowing what challenges may lie ahead, our scientific team has developed a portfolio of enhancement technologies and services, with which these issues will be hopefully addressed. Better solubility, bioavailability, and dissolution rate will help drive drug candidates more quickly to market,” says Marketing Chief of CD Formulation.

After the launch of API chemical modification services, the following services are now available at CD Formulation:

pH Modification Drug Molecular Services

The pH adjustment method is a technique that increases the solubility of ionizable API. Therefore, pH regulators such as acidic and alkaline excipients can be added to the formulation to enhance the solubility and bioavailability.

Drug Salt Formation Services

Salt formation is a very important and key technology in drug development. CD Formulation provides salt screening and testing to facilitate the development of drugs for customers throughout all stages, including the salt selection stage in drug development, formation of the salt form, salt type selection, and characterization of salt.

Drug PEGylation Services

CD Formulation’s experienced team can carry out PEGylation services to meet customers’ needs for proteins, peptides, oligonucleotides and small molecules.

Different Groups of Precursor Drug Design Services

CD Formulation offers the following three precursor drug design services to improve drug bioavailability: sulfonyl prodrug design, cyanide prodrug design, and methyl prodrug design.

In addition to API chemical modification, CD Formulation also offers API physical modification services. However, for either of these modification options, experienced experimental technicians are right there to ensure the objectiveness and integrity of results, together with exquisite experimental operation level, strict experimental control system, and fast data results delivery cycle.

As always, the company aims to bring the best-performing excipients to researchers and help them advance the contracted drug research project to final success. Please visit to explore more of its API chemical modification capabilities.

About CD Formulation

Having served the industry as a custom service provider for various excipient development as well as drug formulation, CD Formulation has made commendable achievements during the last few years. It has accomplished several drug formulation research projects for its customers. Encouraged by these positive results as well as persistent trust from its partners, the company decides to provide a more comprehensive service portfolio for its valued customers worldwide.

Media Contact
Company Name: CD Formulation
Contact Person: Helen Smith
Email: Send Email
Phone: 1-631-372-1052
Country: United States

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Copyright © 2010-2020 & California Media Partners, LLC. All rights reserved.